A clinical-stage company

focused in developing therapeutic
applications
based in aptamer technology.
APTATARGETS
clinical-stage biopharmaceutical using aptamer technology for targeting acute indications.
ApTOLL
(Lead-candidate) is a neuroprotective drug for acute ischemic stroke by targeting inflammation in the acute phase.
Targeting indications
where inflammation causes significant damage, including ischemic stroke, intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.
APTOLL
ApTOLL is the only drug under development to treat stroke by blocking TLR4 activation.
CONTACT US






Avda. Cardenal Herrera Oria, 298. 28035 Madrid, Spain

If you want to know how to get to our facility click here